Dublin, Dec. 04, 2020 (GLOBE NEWSWIRE) — The “Europe Breast Cancer Screening Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Test Type , End User , and Country” report has been added to ResearchAndMarkets.com’s offering.
The European breast cancer screening market was valued at US$ 1,231.82 million in 2019 and is projected to reach US$ 1,586.46 million by 2027; it is expected to grow at CAGR of 4.3% from 2020 to 2027. Increasing incidence of breast cancer and presence of prominent players in the breast cancer screening market, as well as robust research and development activities, are among the prominent factors propelling the market growth. However, the high cost associated with breast cancer screening restrains the growth of the market.
Growing number of breast cancer is mainly due to unhealthy habits, such as smoking, unhealthy diet or infections. As per the Globocan 2019 report, the total number of breast cancer cases in Germany were 71,888 in 2018, and about19,376 breast cancer deaths were reported. Breast cancer is the most common cancer type in Germany. Additionally, according to Cancer Research UK Statistics there were 55,176 new cases of breast cancer and 11,399 cancer deaths from2015 to 2017. Many collaborations are made to spread awareness; for instance, Cancer Research UK and Avon Foundation together launched Avon’s Breast Cancer Promise, a multi-year pledge to educate women about breast cancer. This collaboration promises to reach 100 million women each year with vital information about breast cancer. Moreover, the statistics mentioned that nearly150 new breast cancer cases are diagnosed every day in females. Breast cancer in males is not so common in the UK – as per the cancer research UK there were about 390 new cases in 2017. Furthermore, in Spain, the growing prevalence of breast cancer is likely to demand for screening technologies.
The European breast cancer screening market is segmented into test type and end user. Based on test type, the market is further segmented into imaging test, Immunohistochemistrytest, genetic test, and blood marker test. The imaging test segment held the largest share of the market in 2019 and is anticipated to register the highest CAGR during the forecast period. Based on end user, the market is further segmented into hospitals, diagnostic centers, cancer institute’s, and research laboratories. The hospitals segment held the largest share of the market in 2019; moreover, it is expected to register fastest growth during 2020-2027.
Cancer Center Amsterdam, Food and Drug Administration, World Health Organization (WHO), Centers for Disease Control and Prevention, Instituto Nacional de Cancerologia, and International Diabetes Federation area few essential primary and secondary sources referred to for preparing this report.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in The European Breast Cancer Screening Market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in The European Breast Cancer Screening Market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Key Topics Covered:
1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Breast Cancer Screening Market – By Test Type
1.3.2 Breast Cancer Screening Market – By End User
1.3.3 Europe Breast Cancer Screening Market- By Region
2. Breast Cancer Screening Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Breast Cancer Screening – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe
4.3 Expert Opinion
5. Europe Breast Cancer Screening Market – Industry Dynamics
5.1 Key Drivers
5.1.1 Growing Breast Cancer Cases
5.1.2 Growing Initiatives for Breast Cancer Management
5.2 Key Market Restraints
5.2.1 High Cost Associated With Breast Cancer Screening
5.3 Key Market Opportunities
5.3.1 Product Launches Along With The Technological Advancements In Breast Imaging Modalities
5.4 Future Trends
5.4.1 Growing Agreements And Collaborations For Diagnostic Solutions
5.5 Impact Analysis
6. Breast Cancer Screening Market – Regional Analysis
6.1 Europe Breast Cancer Screening Market Revenue Forecast And Analysis
6.2 Market Positioning of Key Players
7. Breast Cancer Screening Market Analysis – By Test Type
7.1 Overview
7.2 Breast Cancer Screening Market Revenue Share, by Test Type, 2019 and 2027 (%)
7.2.1 Europe Breast Cancer Screening Market, by Test Type – Revenue and Forecast to 2027 (USD Million)
7.3 Blood Marker Test
7.3.1 Overview
7.4 Blood Marker Tests: Breast Cancer Screening Market – Revenue and Forecast to 2027 (US$ Million)
7.5 Imaging Test
7.5.1 Overview
7.5.2 Imaging Test: Breast Cancer Screening Market- Revenue and Forecast to 2027 (US$ Million)
7.6 Genetic Test
7.6.1 Overview
7.6.2 Genetic Test: Breast Cancer Screening Market – Revenue and Forecast to 2027 (US$ Million)
7.7 Immunohistochemistry Test
7.7.1 Overview
7.7.2 Immunohistochemistry Test: Breast Cancer Screening Market – Revenue and Forecast to 2027 (US$ Million)
8. Breast Cancer Screening Market – By End User
8.1 Overview
8.2 Breast Cancer Screening Market, by End User, 2019 and 2027 (%)
8.2.1 Europe Breast Cancer Screening Market, by End User – Revenue and Forecast to 2027 (USD Million)
8.3 Hospitals
8.3.1 Overview
8.3.2 Hospitals: Breast Cancer Screening Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Diagnostics Centers
8.4.1 Overview
8.4.2 Diagnostic Centers: Breast Cancer Screening Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Research Laboratories
8.5.1 Overview
8.6 Research Laboratories: Breast Cancer Screening Market – Revenue and Forecast to 2027 (US$ Million)
8.7 Cancer Institutes
8.7.1 Overview
8.8 Cancer Institutes: Breast Cancer Screening Market – Revenue and Forecast to 2027 (US$ Million)
9. Breast Cancer Screening Market- Regional Analysis
9.1 Europe: Breast Cancer Screening Market
9.1.1 Overview
9.1.2 Europe: Breast Cancer Screening Market – Revenue and Forecast to 2027 (USD Million)
9.1.3 Europe: Breast Cancer Screening Market, by Test Type, 2018-2027 (USD Million)
9.1.4 Europe: Breast Cancer Screening Market, by End User, 2018-2027 (USD Million)
9.1.5 Europe: Breast Cancer Screening Market, by Country, 2018 & 2027 (%)
9.1.6 Germany: Breast Cancer Screening Market – Revenue and Forecast to 2027 (USD Million)
9.1.6.1 Germany: Breast Cancer Screening Market – Revenue and Forecast to 2027 (USD Million)
9.1.6.2 Germany: Breast Cancer Screening Market, by Test Type, 2018-2027 (USD Million)
9.1.6.3 Germany: Breast Cancer Screening Market, by End User, 2018-2027 (USD Million)
9.1.7 UK: Breast Cancer Screening Market – Revenue and Forecast to 2027 (USD Million)
9.1.7.1 UK: Breast Cancer Screening Market – Revenue and Forecast to 2027 (USD Million)
9.1.7.2 UK: Breast Cancer Screening Market, by Test Type, 2018-2027 (USD Million)
9.1.7.3 UK: Breast Cancer Screening Market, by End User, 2018-2027 (USD Million)
9.1.8 France: Breast Cancer Screening Market – Revenue and Forecast to 2027 (USD Million)
9.1.8.1 France: Breast Cancer Screening Market – Revenue and Forecast to 2027 (USD Million)
9.1.8.2 France: Breast Cancer Screening Market, by Test Type, 2018-2027 (USD Million)
9.1.8.3 France: Breast Cancer Screening Market, by End User, 2018-2027 (USD Million)
9.1.9 Spain: Breast Cancer Screening Market – Revenue and Forecast to 2027 (USD Million)
9.1.9.1 Spain: Breast Cancer Screening Market – Revenue and Forecast to 2027 (USD Million)
9.1.9.2 Spain: Breast Cancer Screening Market, by Test Type, 2018-2027 (USD Million)
9.1.9.3 Spain: Breast Cancer Screening Market, by End User, 2018-2027 (USD Million)
9.1.10 Italy: Breast Cancer Screening Market – Revenue and Forecast to 2027 (USD Million)
9.1.10.1 Italy: Breast Cancer Screening Market – Revenue and Forecast to 2027 (USD Million)
9.1.10.2 Italy: Breast Cancer Screening Market, by Test Type, 2018-2027 (USD Million)
9.1.10.3 Italy: Breast Cancer Screening Market, by End User, 2018-2027 (USD Million)
10. Impact of COVID-19 Pandemic On Europe Breast Cancer Screening Market
10.1 Europe: Impact Assessment of COVID-19 Pandemic
11. Breast Cancer Screening Market – Industry Landscape
11.1 Overview
11.2 Growth Strategies in The Breast Cancer Screening Market, 2016-20
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Breast Cancer Screening Market – Key Company Profiles
12.1 General Electric Company
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Siemens Healthineers AG
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Exact Sciences Corporation
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Koninklijke Philips N.V.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Hologic, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 BD
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Myriad Genetics, Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Oncocyte Corporation
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Danaher
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 POC Medical Systems
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About the Publisher
13.2 Glossary of Terms
For more information about this report visit https://www.researchandmarkets.com/r/i2yzlh
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
